WallStreetZenWallStreetZen

NASDAQ: NVCT
Nuvectis Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NVCT

Based on 3 analysts offering 12 month price targets for Nuvectis Pharma Inc

Min Forecast
$11.00+18.66%
Avg Forecast
$15.67+69.01%
Max Forecast
$19.00+104.96%

Should I buy or sell NVCT stock?

Based on 3 analysts offering ratings for Nuvectis Pharma Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NVCT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates NVCT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their NVCT stock forecasts and price targets.

NVCT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-02
lockedlocked$00.00+00.00%2025-03-17
lockedlocked$00.00+00.00%2025-02-25

1 of 1

Forecast return on equity

Is NVCT forecast to generate an efficient return?

Company
119.21%
Industry
145.91%
Market
81.63%
NVCT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NVCT forecast to generate an efficient return on assets?

Company
62.23%
Industry
35.93%
NVCT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NVCT earnings per share forecast

What is NVCT's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.16
Avg 2 year Forecast
-$1.38
Avg 3 year Forecast
-$0.27

NVCT revenue forecast

What is NVCT's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$62.3M
Avg 2 year Forecast
$71.4M
Avg 3 year Forecast
$184.1M

NVCT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NVCT$9.27$15.67+69.01%Strong Buy
PROK$0.75N/AN/A
HUMA$1.37$19.00+1,286.86%Strong Buy
PRME$1.69$13.50+698.82%Strong Buy
CRGX$4.60$15.00+226.09%Buy
View Top Biotech Stocks

Nuvectis Pharma Stock Forecast FAQ

Is Nuvectis Pharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: NVCT) stock is to Strong Buy NVCT stock.

Out of 3 analysts, 2 (66.67%) are recommending NVCT as a Strong Buy, 1 (33.33%) are recommending NVCT as a Buy, 0 (0%) are recommending NVCT as a Hold, 0 (0%) are recommending NVCT as a Sell, and 0 (0%) are recommending NVCT as a Strong Sell.

If you're new to stock investing, here's how to buy Nuvectis Pharma stock.

What is NVCT's earnings growth forecast for 2025-2027?

(NASDAQ: NVCT) Nuvectis Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.12%.

Nuvectis Pharma's earnings in 2025 is -$19,000,000.On average, 2 Wall Street analysts forecast NVCT's earnings for 2025 to be -$27,134,139, with the lowest NVCT earnings forecast at -$29,005,459, and the highest NVCT earnings forecast at -$25,262,819. On average, 2 Wall Street analysts forecast NVCT's earnings for 2026 to be -$32,163,311, with the lowest NVCT earnings forecast at -$38,128,143, and the highest NVCT earnings forecast at -$26,198,479.

In 2027, NVCT is forecast to generate -$6,315,705 in earnings, with the lowest earnings forecast at -$43,742,103 and the highest earnings forecast at $31,110,694.

What is NVCT's revenue growth forecast for 2027-2029?

(NASDAQ: NVCT) Nuvectis Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.33%.

Nuvectis Pharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast NVCT's revenue for 2027 to be $1,456,822,558, with the lowest NVCT revenue forecast at $1,456,822,558, and the highest NVCT revenue forecast at $1,456,822,558. On average, 2 Wall Street analysts forecast NVCT's revenue for 2028 to be $1,669,802,156, with the lowest NVCT revenue forecast at $39,765,548, and the highest NVCT revenue forecast at $3,299,838,764.

In 2029, NVCT is forecast to generate $4,307,076,711 in revenue, with the lowest revenue forecast at $4,307,076,711 and the highest revenue forecast at $4,307,076,711.

What is NVCT's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: NVCT) forecast ROA is 62.23%, which is higher than the forecast US Biotechnology industry average of 35.93%.

What is NVCT's Price Target?

According to 3 Wall Street analysts that have issued a 1 year NVCT price target, the average NVCT price target is $15.67, with the highest NVCT stock price forecast at $19.00 and the lowest NVCT stock price forecast at $11.00.

On average, Wall Street analysts predict that Nuvectis Pharma's share price could reach $15.67 by Apr 2, 2026. The average Nuvectis Pharma stock price prediction forecasts a potential upside of 69.01% from the current NVCT share price of $9.27.

What is NVCT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NVCT) Nuvectis Pharma's current Earnings Per Share (EPS) is -$1.11. On average, analysts forecast that NVCT's EPS will be -$1.16 for 2025, with the lowest EPS forecast at -$1.24, and the highest EPS forecast at -$1.08. On average, analysts forecast that NVCT's EPS will be -$1.38 for 2026, with the lowest EPS forecast at -$1.63, and the highest EPS forecast at -$1.12. In 2027, NVCT's EPS is forecast to hit -$0.27 (min: -$1.87, max: $1.33).

What is NVCT's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: NVCT) forecast ROE is 119.21%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.